Text Size A A A

Sun Pharma In The News

Tell a Friend Print Home » Media » Sun Pharma In The News

Sun, Merck team up to mkt diabetes drugs

 

Merck and Sun Pharma have entered into a partnership for marketing blockbuster diabetes drug Si-tagliptin and one of its com'bination in the country. Un'der the India-specific agre'ement, Sun Pharma will market the anti-diabetes dru'gs under different brand na'mes, while MSD (Merck), which holds the patent, will continue to market Sitaglip-tin as Januvia. Recently, US-based Merck entered into a joint venture with Sun Phar'ma to develop and commer'cialize branded generics in emerging markets.
 
The anti-diabetes market posted a strong double-digit growth last year, and is esti'mated to be around Rs 2,100 crore, according to IMS. The market for sitagliptin'a rel'atively new class of anti-dia'betes drug (DPP4 inhibitors) 'is also showing a steady growth and is estimated to be around Rs 90 crore. The Sun Pharma scrip ended flat at Rs 445 on the BSE on Monday.
In another development, Merck's net profit fell 12.76% to Rs 13.39 crore in the first quarter ended March 31, over the same period last fiscal. The company had a net profit of Rs 15.35 crore in Ql, 2010, Merck said in a filing to the Bombay Stock Exchange. The Merck scrip ended the day at Rs 662, up over 5%.
 
The company posted a to'tal income of Rs 116 crore for the quarter ended March, 2011, as against Rs 105 crore for the corresponding period last fiscal.
 
Elaborating on the partnership, K G Ananthakrish-nan, managing director of MSD in India said it is fo'cused on increasing the mar'ket access of Sitagliptin and Sitagliptin plus Metformin in India, which is an urgent need, given the high disease burden of type 2 diabetes in India and the role these drugs play in helping to ad'dress the threat. Both part'ners complement each oth'er's strengths in this arrangement. "While MSD in India brings the scientific excellence and market suc'cess of the compound to the partnership, Sun Pharma brings its proven success and expertise in the marketing of drugs in the relevant ther'apeutic areas across India," he said.
 
Kalyanasundaram, chief executive officer Sun Phar'ma, said, "Through this part'nership, the reach of Sita'gliptin and Sitagliptin plus Metformin will be enhanced among doctors and patients in India, helping them effica'ciously manage the disease."